手机看黄色大片1024,亚洲v无码一区二区三区四区观看,黄真人在线观看高清无码,极品嫩模大尺度av在线播放免费观看

產品資料

LS 174T細胞

如果您對該產品感興趣的話,可以
產品名稱: LS 174T細胞
產品型號: LS 174T
產品展商: HZbscience
產品文檔: 無相關文檔

簡單介紹

LS 174T細胞應如何避免細胞污染,細胞污染的種類可分成**、酵母菌、霉菌、病毒和霉漿菌。主要的污染原因為無菌操作技術不當、操作室環境不佳、污染之血清和污染之細胞等。嚴格之無菌操作技術、清潔的環境、與品質良好之細胞來源和培養基配制是減低污染之*好方法。LS 174T細胞何時須更換培養基?視細胞生長密度而定,或遵照細胞株基本數據上之更換時間,按時更換培養基即可。


LS 174T細胞  的詳細介紹

LS 174T細胞

細胞形態: 上皮樣

ATCC Number: CL-188?

相關**: 大腸癌

生長狀態: 貼壁生長

運輸方式: 凍存運輸

數量: 大量

器官來源: 結腸

是否是腫瘤細胞: 1

物種來源: 人

年限: Dukes' type B

LS 174T細胞Designations: LS 174T

Depositors: Northwestern University

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial


Source: Organ: colon

Tumor Stage: Dukes' type B

Disease: colorectal adenocarcinoma

Cellular Products: carcinoembryonic antigen (CEA) (The production of CEA in the ATCC seed stock was 1944 ng per 10(6) cells in 10 days.)

interleukin 10 (IL-10) [22511]

interleukin 6 (IL-6)

mucin

LS 174T細胞Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Tumorigenic: Yes

Oncogene: myc +; myb + ; ras +; fos +; p53 +; sis -; abl -; ros -; src -

Antigen Expression: serologically defined colon cancer antigen 3; Homo sapiens, expressed

HLA A2, B13, B50; Blood type O

DNA Profile (STR): Amelogenin: X

CSF1PO: 10, 13, 14

D13S317: 10

D16S539: 11, 13

D5S818: 11, 15

D7S820: 11

THO1: 6, 7

TPOX: 8, 9

vWA: 15, 17

Cytogenetic Analysis: LS 174T細胞45,X; one X chromosome missing; no other chromosomal aberrations

Age: 58 years

Gender: female

Ethnicity: Caucasian

Comments: LS 174T is a variant of LS 180 (ATCC CL-187) that has been maintained by using trypsin in the subculture protocol. It is more easily subcultivated than that parent line and, like LS 180, it is reported to produce large amounts of carcinoembryonic antigen (CEA).

Electron microscopic studies revealed abundant microvilli and intracytoplasmic mucin vacuoles [Pubmed ID: 1262041].

They are negative for p53 antigen expression, but positive for mRNA expression.

LS 174T cells stain positively for cytokeratins.

The line is positive for expression of c-myc, N-myc, H-ras, N-ras.

Myb, and fos oncogenes.

K-ras and sis oncogene expression were not detected.

Propagation: LS 174T細胞ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Temperature: 37.0°C

Subculturing: Protocol:

Remove and discard culture medium.

Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.

Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).

Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.

Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.

Add appropriate aliquots of the cell suspension to new culture vessels.

Incubate cultures at 37?C.


Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended

Medium Renewal: 2 to 3 times per week

Preservation: LS 174T細胞Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO

Storage temperature: liquid nitrogen vapor phase

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003

recommended serum:ATCC 30-2020

derived from same individual:ATCC CL-187

References: 2148: Tom BH, et al. Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 12: 180-191, 1976. PubMed: 1262041

3524: Tom BH, et al. Process of producing carcinoembryonic antigen. US Patent 4,228,236 dated Oct 14 1980

22147: Chen TR, et al. Intercellular karyotypic similarity in near-diploid cell lines of human tumor origins. Cancer Genet. Cytogenet. 10: 351-362, 1983. PubMed: 6652615

22511: Gastl GA, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int. J. Cancer 55: 96-101, 1993. PubMed: 8344757

22861: Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874

32265: Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066

32377: Shibata D, et al. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat. Genet. 6: 273-281, 1994. PubMed: 8012390

32794: Kutchera W, et al. Protaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl. Acad. Sci. USA 93: 4816-4820, 1996. PubMed: 8643486


滬公網安備 31011702004356號